Journal: bioRxiv

Article Title: Clonal morphology-guided combination therapies overcome heterogeneity-driven drug tolerance

doi: 10.64898/2026.01.31.703021

Figure Lengend Snippet: A-B. Proliferation inhibitory effects of long-term (5-day) versus short-term (2-day) treatment with the chemotherapy drug gemcitabine (A) and the targeted drug MK-2206 (B). The parental EO771 cell line was used to determine the effective inhibitory dose range for each drug. C. Schematic illustrating the analysis of the effective inhibitory dose range following long-term drug treatment. This range is defined as spanning from the maximum inhibitory concentration (MaxIC) to the minimum inhibitory concentration (MinIC). D. Schematic outlining the assessment of drug-induced lethal effects. Cells treated within the effective inhibitory dose range were evaluated for their ability to proliferate upon re-plating; a lack of subsequent growth indicates a cytotoxic (lethal) effect rather than a cytostatic (growth-inhibitory) effect. E. Inhibitory effects of eight drugs, each applied within its effective dose range, on the parental EO771 line and the three EM clones. F. Drug response profiles of the three EM clones relative to the parental EO771 line across the eight-drug panel.

Article Snippet: Chemotherapy drugs: 5-Fluorouracil (5-FU, S1209), Gemcitabine (GEM, S1714), Cytarabine (Ara-C, S1648), Methotrexate (MTX, S1210), Paclitaxel (PTX, S1150), Vincristine (VCR, S1241), Topotecan (TPT, S1231), Doxorubicin (DOX, S1208), Cisplatin (CDDP, S1166), Oxaliplatin (OXA, S1224), were purchased from Selleck, USA.

Techniques: Concentration Assay, Clone Assay

Journal: BMC Pharmacology & Toxicology

Article Title: A novel nitidine chloride nanoparticle overcomes the stemness of CD133 + EPCAM + Huh7 hepatocellular carcinoma cells for liver cancer therapy

doi: 10.1186/s40360-022-00589-z

Figure Lengend Snippet: a . Representative organ images showing specific tumor targeting of rhodamine B isothiocyanate labeled TPGS-FA/NC nanoparticles 8 h post-injection into mice bearing Huh7 xenograft (T: tumor, Li: liver, H: heart, L: lung, K:kidney, S: spleen, and B:brain; Color scale: radiant efficiency, [p s − 1 cm − 2 sr − 1 ] [μWcm − 2 ] − 1 ). V b . Quantitative analysis of biodistribution in tumors and normal organs, quantified from the organ images. Intravenous treatment of nude mice bearing orthotopic Huh7 xenografts with TPGS-FA/NC nanoparticles (red) and control groups (turquoise: NC, fuchsia:5-Fu, blue: PBS) every other day for a total of five injections (4 mg kg − 1,NC per body weight, indicated by arrows). c . Mice body weight was monitored during the time course of treatments ( n = 5 biologically independent animals, statistics was calculated by two-tailed unpaired t-test presented as mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001, p = 4.3 × 10 − 3 ,3.4 × 10 − 3 and 5.0 × 10 − 4 comparing TPGS-FA/NC to NC,5-Fu and PBS, respectively). d . Representative images of liver cancer tumors harvested from mice after treatments * p < 0.05, ** p < 0.01, *** p < 0.001; p = 0.01, 8 × 10 − 4,and 2 × 10 − 4 comparing TPGS-FA/NC to NC, 5-Fu, and PBS, respectively. Source data are provided as a

Article Snippet: 5-fluorouracil (5-Fu) was purchased from MedChemExpress (MCE, Monmouth Junction, NJ, USA).

Techniques: Labeling, Injection, Control, Two Tailed Test

Journal: Frontiers in Immunology

Article Title: Fluoropyrimidine-associated gastrointestinal toxicity: pharmacovigilance reporting signals and in vitro evidence of epithelial injury, barrier impairment, and inflammatory responses

doi: 10.3389/fimmu.2026.1934652

Figure Lengend Snippet: Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, capecitabine, trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.

Article Snippet: 5-Fluorouracil (5-FU,TargetMol, USA, T0984), capecitabine (TargetMol, USA,T1408), and trifluridine ( T70086 ,Psaitong Biotechnology, Beijing,China.)

Techniques: Analysis

Journal: Oncotarget

Article Title: Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism

doi: 10.18632/oncotarget.27815

Figure Lengend Snippet: ( A ) Graph of cell cycle kinetics data comparing Mubritinib (MUB) to cytarabine (CYT) and rapamycin (RAP). DMSO and camptothecin (CPT) were used as controls. PEL cells (BC1 and BCBL1) treated with 7.5 nM Mubritinib show a significant decrease in the total population of S and G2 cells that is not observed for BJAB or LCL352 cells. Neither cytarabine nor rapamycin showed similar selectivity for inhibition of PEL cell growth (S, G2) ( ** p < 0.001, * p < 0.05; Student’s T Test). ( B ) Cell cycle profiles comparing cells (BJAB, BC1, BCBL1, and LCL352) treated with DMSO and 15 nM Mubritinib measured by FACS flow cytometry analysis of propidium iodide staining. ( C ) Flow cytometry analysis of Annexin V/PI staining comparing cells (BJAB, BC1, BCBL1, LCL352) treated with DMSO and 15 nM Mubritinib. ( D ) Graphs summarizing the decrease in live cell populations observed from the Annexin V/PI experiment. Camptothecin (4 mM) and Cytarabin (1 mM) are shown for comparison. ( ** p < 0.001; Mann–Whitney). ( E ) ChIP-qPCR assay for LANA or IgG control in BCBL1 cells treated with Mubritinib (15 nM) for 72 hrs with primers for KSHV TR, control region a, or cellular Actin. ( F ) Western blot control of ChIP assays showing LANA, RTA, Actin, or gH2AX in BCBL1 cells at 48 h after addition of DMSO (–) or Mubritinib (15 nM) (+).

Article Snippet: Adrucil (228440010) and Cytarabine (449561000) were purchased from Acros Organics.

Techniques: Inhibition, Flow Cytometry, Staining, Comparison, MANN-WHITNEY, ChIP-qPCR, Control, Western Blot